regulatory
The orthopedic device, intended for bunion correction, secured a 'Special' clearance, indicating substantial equivalence to a predicate device.
Nvision Biomedical Technologies has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for its EnHAnce PEEK Bunion System. The decision, dated September 18, 2026, classifies the device as substantially equivalent to existing devices on the market.
This clearance falls under product code HRS, a classification for orthopedic devices. The FDA's Orthopedic Advisory Committee oversees devices within this category.
The EnHAnce PEEK Bunion System is a Class II medical device, indicating a moderate risk profile. Its regulation number is 888.3030, which pertains to custom surgical kits and instruments. The clearance type was designated as 'Special', often applied when modifications to an existing cleared device do not raise new questions of safety or effectiveness. A summary document was provided for the filing, as is typical for 510(k) submissions.
Details regarding the specific design features, material advantages of PEEK (polyetheretherketone), or clinical indications beyond bunion correction are not detailed in the public clearance record. Nvision Biomedical Technologies has not yet publicly disclosed comprehensive clinical data or market availability timelines for this system.
The 510(k) pathway, specifically a 'Special' 510(k), allows for certain modifications to a manufacturer's own legally marketed predicate device. This process typically requires less data than a traditional 510(k) if the changes do not affect the fundamental scientific technology or intended use. The 'Substantially Equivalent' decision means the FDA determined the new device is as safe and effective as a legally marketed predicate device, and does not raise new questions of safety or effectiveness.